SVS:CA

Launch of the World's First Organic Omega-3 - Ocean Based

(TheNewswire)



February 2, 2021 TheNewswire - Eversea TM America Inc. ("Eversea" or the " Company " ) (TSXV:SVS) is pleased to announce launch of the world's first and only organic certified Omega-3 DHA chewable for children. The product is a unique first offering for Eversea, using the world's only EU and USDA organic certified DHA ingredient Nanuq TM Omega3 100 (pronounced Na Nook).  This patented ingredient is the product of 7 years of research and development into the development of ocean-based Omega-3 without using chemical process aidsadditives, solvents or heavy industrial processes. We grow the product indoors in sterilized stainless steel to ensure the highest quality, which prevents environmental contamination. The ingredient has obtained FDA NDI (New Dietary Ingredient) status. Nanuq Omega-3 100 is the only sustainable plant-based Omega-3 DHA in the world suitable for customers that demand clean, green and organic products.

Fish Free and Feeling Good

Over a 100 Billion Fish a Year Used for Omega-3 Supplementation

The first product is a gummy-like children's supplement that we call a Fruit Drop. It contains over 80% dried organic fruit, has no added sugar and is tested free of all common allergens. It is plant-based and non-GMO. This is a meticulous organic product, processed without nutrient degrading industrial processing or chemicals, resulting in a clean whole food Omega-3. Parents can feel good about feeding their children a wholesome and healthy supplement. WE can also feel good about protecting our oceans. Each bottle saves 6 fish when compared to consuming fish oil from the pacific anchovy fishery, where the great majority of our global supply of Omega 3 fish oil for supplements comes from. The first flavor is Zing Fruit, which can best be described as orange zest with some sweetness coming from the dried fruit. Eversea intends to continue developing products ranging from new fruit drop flavors to adult food boosters and superfoods - all organic.


Click Image To View Full Size

Look for Nanuq!

The Zing Fruit Drop children's 90's is available through the company's e-commerce web site at www.eversea.ca and Amazon, both only in the USA. Social media awareness and Facebook advertising has just commenced.

Our patented Nanuq ingredient is the world's first ocean-based Omega-3 (DHA) that is organic. It is certified organic in the EU and by the USDA.

Our Nanuq logo appears on Omega-3 products to confirm they are truly organic. Check your health products, your food labels, and your nutraceuticals for the Nanuq logo. If the bear is not there, it's not organic Nanuq Omega-3.

ABOUT EVERSEA, A NEW KIND OF COMPANY

Our product, values, and purpose are aligned. We believe in a bright life for all people AND the planet. Eversea's unique organic certified ingredient Nanuq (pronounced Na-Nook) Omega-3 is produced without depleting the ocean. This means we can enhance your health while saving fish or krill. Also, a portion of our profits go to support the ocean and the environment. We have a team of talented individuals who are committed to bringing you the very best (and healthiest) organic products available. We believe in the value of long-chain (ocean-based) Omega-3 because your supplements should be as healthy as possible. That's why we made sure our products were developed without solvents or chemicals and contain only wholesome recognizable ingredients. Years of work were spent becoming experts at only using organic nutrients to grow an ocean high Omega-3 algae. We did it because we want the best for children, ourselves and for you -- our customers! Please enjoy our products with confidence and the knowledge that Eversea's Omega-3 products are like no others available in the world.

For further information:    www.eversea.ca     Email: info@eversea.ca

Eversea Inc. is a wholly owned division of Solarvest BioEnergy Inc. (TSXV: SVS )

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×